FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Postoperative Pain

Therapeutic area intelligence for Postoperative Pain with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

ropivacaine →

YZJ-4729 →

Recent signals(2)

ClinicalJuly 28, 2026

Study on Ropivacaine Plus Triamcinolone for Postoperative Pain Relief After VATS

A multicenter, randomized controlled trial is investigating the efficacy of preemptive incisional infiltration with ropivacaine plus triamcinolone versus ropivacaine alone for postoperative pain relief after thoracoscopic surgery.

ClinicalJuly 7, 2026

YZJ-4729 Shows Promise in Phase Ⅱ Trial for Postoperative Pain Relief

A Phase Ⅱ study is evaluating the efficacy and safety of YZJ-4729 in patients with moderate to severe acute pain after abdominal surgery.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.